Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company building a portfolio of therapies for rare and serious diseases. The Company's portfolio includes ZEVASKYN (prademagene zamikeracel), the autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB); ABO-801, a Phase III-ready product candidate for eosinophilic esophagitis (EoE); and ABO-701 (PSMA-SIR-T), an investigational engineered T-cell therapy targeting Prostate-Specific Membrane Antigen (PSMA). ZEVASKYN is a type of gene therapy made from a patient's own skin cells that is surgically applied to treat wounds in both children and adults who have RDEB. The Company's fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. ABO-801 is a once-daily oral disintegrating tablet formulation of fluticasone propionate.